Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,831

How to avoid the adverse reactions of senolytics through better design

Another biomarker of senescent cells could be p16, a protein whose levels increase when cells stop dividing if old and also a protein whose gene is turned off in many human cancers.

Coming back to our topic – designing senolytics that avoid the apoptosis of young, healthy cells – the ideal senolytic should accomplish two things: –turn on p53 at increased levels to determine stubborn, senescent cells to commit suicide –do that on senescent cells only.

And in order to accomplish the second part, such a drug should be ‘programmed’ to only act on those cells where it recognizes senescence-associated biomarkers. There is no single biomarker today that stains positive or negative on all types of senescence cells, but increased levels of beta-galactosidase and p16 proteins could be a welcome start to identify old cells in vivo when designing such a drug.

Random mutations play large role in cancer, study finds

Genomic instability (mutations) has been suggested as being one of the primary hallmarks of aging and this research might support that idea. Researchers at John Hopkins report that around 66% of mutations in cancer cells are due to random errors with environment/lifestyle contributing 29% and 5% inherited.

“That finding challenges the common wisdom that cancer is the product of heredity and the environment. “There’s a third cause and this cause of mutations is a major cause,” says cancer geneticist Bert Vogelstein.”

“Such random mutations build up over time and help explain why cancer strikes older people more often. Knowing that the enemy will strike from within even when people protect themselves against external threats indicates that early cancer detection and treatment deserve greater attention than they have previously gotten, Vogelstein says.”

Solar-Powered Graphene Skin Enables Prosthetics to Feel

The team tested their device on a prosthetic hand. When the skin patches on the skin were enabled, the prosthetic could touch and grab soft objects like a normal hand. But when the skin was not turned on, the hand crushed the objects.

The skin requires just 20 nanowatts of power per square centimeter, according to the paper. Right now, the energy captured by the photovoltaic cells has to be used immediately, but the team has another prototype in development that includes flexible supercapacitors to store excess energy.

They are also working on scaling up the material to cover larger areas of a prosthetic or robot, using a method the team pioneered in 2015 for inexpensively producing large sheets of graphene. Dahiya expects the skin will eventually be produced for just $1 for 5 to 10 centimeters of the material.

Research Suggests Periodic Fasting Might Reverse Type 1 Diabetes

Fasting might help T1 diabetics according to new research.

Periodic fasting has long been demonstrated to have beneficial effects on autoimmune disorders, cancer prevention and treatments, cardiovascular disease and a myriad of other ailments. This most recent paper by Cheng et al. may add the treatment of Type 1 diabetes to that list[1]. If successful in humans it has the potential to reverse some or most of the loss of insulin producing cells within the pancreas. Just as remarkable, the treatment itself is relatively straightforward, consisting of a regimented protocol of periodic fasting-like conditions.

Generally speaking, Type 1 diabetes results from an autoimmune mediated depletion of insulin secreting pancreatic beta islet cells. In contrast, Type 2 results from lower cellular sensitivity to insulin. Type 2 is primarily caused by environmental factors such as poor diet.

The current medical approach to treating Type 1 diabetes is the periodic administration of insulin, usually through self-administered injections. Most new therapies focused on curing Type 1 diabetes are looking to repopulating beta islet cells through the use of reprogrammed induced pluripotent stem (iPS) cells.

Scientists create tiny female reproductive system in a dish

March 28 (UPI) — Researchers at Northwestern University created a synthetic version of the female reproductive system that can be used to test drug therapies.

The system is shaped like a cube and consists of a series of small tubes, each containing cells from a different part of the female reproductive system, including the uterus, cervix, vagina, fallopian tubes and liver.

The system is called Evatar, like avatar but with an E for Eve, because it reproduces the female reproductive tract and mimics the hormones of the full-size reproductive system.

How The Power Of Synthetic Biology could reshape the world

Mushroom buildings, jurassic park and terraforming.

Did you ever hear about synthetic biology? No? Imagine that we could alter and produce DNA from scratch just like an engineer. Doesn’t it sound like one of the greatest interdisciplinary achievements in recent history?

Think about it, a bio-technologist is doing more or less the work of a programmer but instead of using a computer language he’s doing it by arranging molecules embedded in every living cell. The outcome, if ever mastered, could reshape the world around us dramatically.

Rapamycin: An impressive geroprotector with a few fatal flaws

A look at Rapamycin the life extending drug with some serious drawbacks.

If any drug has performed consistently and unequivocally well in anti-aging trials, it’s rapamycin. Dr. Matt Kaeberlein’s Dog Aging Project is among the most recent trials investigating its longevity-promoting potential in mammals, but it’s also been the subject of numerous trials in mice, worms, flies and yeast. And although it acts through a mechanism which has been most closely associated cancer prevention, this drug appears to stave off all maladies related to aging.

Even more encouraging are the indications that it could be beneficial well into old age. Trials done in the National Aging Institute’s ITP, a testing protocol that collects its data from three independent labs, found that when mice started rapamycin treatment at 600 days old (roughly 60 in human years), they lived an average of 11% longer than control counterparts. Longevity interventions that hold up well even in late-life are few and far between, and even the traditionally successful method of caloric restriction has limited utility when begun late.

Coincidentally, some think that caloric restriction works via the same pathway as rapamycin: by inhibiting the enzyme mTOR. Among its numerous functions, mTOR helps to drive cell growth and proliferation. Halting out of control cell division is key to cancer prevention, and so it’s not too surprising that rapamycin treatment counters development of certain types of tumors by inhibiting mTOR. It can have detrimental effects on nutrient sensing, the factor behind metabolic diseases like diabetes, by promoting activation of insulin receptors. And since mTOR is responsible for increasing energy consumption and cellular metabolism, it can also produce oxidative stress by way of the free radicals created by overactive mitochondria.

Capacitively coupled arrays of multiplexed flexible silicon transistors for long-term cardiac electrophysiology

Advanced capabilities in electrical recording are essential for the treatment of heart-rhythm diseases. The most advanced technologies use flexible integrated electronics; however, the penetration of biological fluids into the underlying electronics and any ensuing electrochemical reactions pose significant safety risks. Here, we show that an ultrathin, leakage-free, biocompatible dielectric layer can completely seal an underlying array of flexible electronics while allowing for electrophysiological measurements through capacitive coupling between tissue and the electronics, without the need for direct metal contact. The resulting current-leakage levels and operational lifetimes are, respectively, four orders of magnitude smaller and between two and three orders of magnitude longer than those of other flexible-electronics technologies. Systematic electro­physiological studies with normal, paced and arrhythmic conditions in Langendorff hearts highlight the capabilities of the capacitive-coupling approach. These advances provide realistic pathways towards the broad applicability of biocompatible, flexible electronic implants.